Youhong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5353853/publications.pdf

Version: 2024-02-01

17	464	840776 11	888059 17
papers	citations	h-index	g-index

17	17	17	830
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Visualizing Peroxynitrite Fluxes in Endothelial Cells Reveals the Dynamic Progression of Brain Vascular Injury. Journal of the American Chemical Society, 2015, 137, 12296-12303.	13.7	188
2	A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation. Antimicrobial Agents and Chemotherapy, 2015, 59, 7061-7072.	3.2	44
3	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. ACS Medicinal Chemistry Letters, 2017, 8, 830-834.	2.8	40
4	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. European Journal of Medicinal Chemistry, 2021, 209, 112868.	5.5	32
5	Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. European Journal of Medicinal Chemistry, 2015, 95, 302-312.	5.5	28
6	Direct Câ€“H functionalization of difluoroboron dipyrromethenes (BODIPYs) at Î²-position by iodonium salts. RSC Advances, 2018, 8, 5542-5549.	3.6	18
7	Phase Transfer Reagent Promoted Tandem Ring-Opening and Ring-Closing Reactions of Unique 3-(1-Alkynyl) Chromones. Organic Letters, 2015, 17, 2134-2137.	4.6	16
8	Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica, 2014, 35, 89-97.	6.1	15
9	Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 191-200.	5.5	14
10	Design and Synthesis of Novel Arctigenin Analogues for the Amelioration of Metabolic Disorders. ACS Medicinal Chemistry Letters, 2015, 6, 386-391.	2.8	13
11	Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5679-5684.	2.2	11
12	Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. European Journal of Medicinal Chemistry, 2017, 126, 122-132.	5.5	11
13	Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors. European Journal of Medicinal Chemistry, 2018, 145, 328-337.	5.5	11
14	Bicyclo[2.2.1]heptane containing N,Nâ€²-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents. RSC Advances, 2018, 8, 11061-11069.	3.6	8
15	Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold. European Journal of Medicinal Chemistry, 2022, 236, 114259.	5.5	8
16	The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation. Molecular Cancer Therapeutics, 2021, 20, 2198-2206.	4.1	6
17	Discovery of 1,5-Dihydro-4H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2. ACS Medicinal Chemistry Letters, 2021, 12, 836-845.	2.8	1